BSX (Boston Scientific Inc) EV/EBITDA Multiple
Boston Scientific (BSX) maintains a diversified portfolio ranging from cardiology to endoscopy that stabilizes revenues, as confirmed by the EV/EBITDA ratio chart with historical data, where the current mark is 12.57. The company generates profit from the sale of minimally invasive stents and neuromodulators. Business efficiency is supported by plant modernization and the automation of quality control, which minimizes production risks and equipment downtime.
Summary analytical data breakdowns for bostonscientific.com (BSX)
- stock price and consensus target price:
- business market valuation indicators:
- issuer book value statistics:
- debt and liquidity data:
Debt to Equity Boston Scientific|BSX - Long-Term Debt to Equity Ratio|Short-Term Debt to Capital Boston Scientific Corporation|BSX - Company Cumulative Debt|Debts to Book Capitalization Boston Scientific Corporation Inc.|BSX - Company Long-Term Indebtedness|Company Short-Term Debts Boston Scientific|Quick Ratio bostonscientific.com
- financial results and valuation multiples details:
BSX - Net Income|Projected Future Earnings Boston Scientific|BSX - P/E Multiple|Future Price to Earnings Boston Scientific|BSX - Price/Earnings to Growth Ratio|Enterprise Value to EBITDA Ratio Boston Scientific Corporation Inc.|BSX - Income before deduction of interest, taxes and amortization|Net earnings per share (EPS TTM) Boston Scientific|BSX - Net earnings per one share for the last twelve months|Year-over-year earnings per share growth for the last twelve months bostonscientific.com|BSX - Net earnings per share change in current year|Expected earnings per share growth for next year Boston Scientific
Initial company analysis:Boston Scientific Inc BSX
Analyzing debt load and operational efficiency is critical for assessing the resilience of Boston Scientific (BSX) to market volatility. Innovations in cardiology and endoscopy create high switching costs for equipment, ensuring a stable cash flow. In a historical context, the company's EV/EBITDA ratio determines the payback period for the total business value through earnings before interest, taxes, depreciation, and amortization. This metric allows for an objective assessment of the asset's fundamental value by excluding the impact of accounting policies.
Competitor analysis for Boston Scientific
Edwards Lifesciences Corp - Enterprise Value to EBITDA Ratio|RMD (ResMed Corporation) - Company Value to Operating Income Before Depreciation Ratio|Insulet Corporation - EV/EBITDA Multiple|Company Value to EBITDA Zimmer Biomet Holdings Inc|COO: EV/EBITDA Multiple|Enterprise Value to Operating Income Before Depreciation ALGN|Enterprise Value to EBITDA Ratio GMED|TMDX: Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Alphatec Holdings, Inc. (ATEC)|Enterprise Value to EBITDA Ratio artivion.com AORT|EV/EBITDA Multiple ENOV (Enovis)|Integra LifeSciences Corp (IART) - Company Value to EBITDA|Motiva - EV/EBITDA Multiple|BBNX (iLet Bionic Pancreas) - Enterprise Value to Operating Income Before Depreciation|IRMD: EV/EBITDA Multiple|EMBC - Total Company Value to Operating Income Before Depreciation Ratio|TNDM (Tandem Diabetes Care, Inc.) - EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio AxoGen Inc (AXGN)|EV/EBITDA Multiple SIBN|EV/EBITDA Multiple Orthofix Corp (OFIX)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Bioventus Inc. BVS|OrthoPediatrics Corp - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|TMCI: Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation SRTA (Blade Air Mobility)|CARL: EV/EBITDA Multiple|Company Value to EBITDA RxSight Ophthalmic (RXST)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization ClearPoint Neuro Inc.|STXS - Enterprise Value to EBITDA Multiple|Enterprise Value to EBITDA Ratio STIM (Neuronetics)|EV/EBITDA Multiple Sight Sciences Inc. (SGHT)|EV/EBITDA Multiple OBIO (Orchestra BioMed)|Total Company Value to Operating Income Before Depreciation Ratio Anika Therapeutics Inc. (ANIK)|NSPR - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to Operating Income Before Depreciation Ratio ZJYL|vivani.com (VANI) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to EBITDA Ratio Xtant Medical|NMTC (NeuroOne Corp) - EV/EBITDA Multiple|Company Value to EBITDA Modular Med MODD|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Myomo, Inc. (MYO)|envoymedical.com - Enterprise Value to Operating Income Before Depreciation|Vivos Therapeutics, Inc. - Enterprise Value to EBITDA Ratio|Enterprise Value to Operating Income Before Depreciation Ratio NVNO (enVVeno Medical Corporation)|SINTX Technologies - EV/EBITDA Multiple|TNON: Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|ReWalk Robotics Ltd. (LFWD) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to EBITDA Autonomix Medical (AMIX)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization INVO Fertility|Bone Biologics Corp. (BBLG) - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to EBITDA Ratio AXNX (Axonics Modulation Technologies)|Enterprise Value to Operating Income Before Depreciation Ratio BIOL|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Dynatronics DYNT|Paragon 28 Inc. (FNA) - Company Value to EBITDA|INVO - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization
